Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

被引：404

作者：

Jenkins, Russell W. ^{[1
,2
]}

Aref, Amir R. ^{[1
,3
]}

Lizotte, Patrick H. ^{[1
,3
]}

Ivanova, Elena ^{[1
,3
]}

Stinson, Susanna ^{[4
]}

Zhou, Chensheng W. ^{[1
,5
]}

Bowden, Michaela ^{[1
,5
]}

Deng, Jiehui ^{[1
]}

Liu, Hongye ^{[1
,3
,6
]}

Miao, Diana ^{[1
,7
,8
]}

He, Meng Xiao ^{[1
,7
,8
,9
]}

Walker, William ^{[1
,3
]}

Zhang, Gao ^{[10
,11
]}

Tian, Tian ^{[12
]}

Cheng, Chaoran ^{[12
]}

Wei, Zhi ^{[12
]}

Palakurthi, Sangeetha ^{[1
,3
]}

Bittinger, Mark ^{[1
,3
]}

Vitzthum, Hans ^{[2
]}

Kim, Jong Wook ^{[1
,7
,8
]}

Merlino, Ashley ^{[1
]}

Quinn, Max ^{[1
]}

Venkataramani, Chandrasekar ^{[4
]}

Kaplan, Joshua A. ^{[4
]}

Portell, Andrew ^{[1
,3
]}

Gokhale, Prafulla C. ^{[1
,3
]}

Phillips, Bart ^{[4
]}

Smart, Alicia ^{[1
,7
,8
]}

Rotem, Asaf ^{[1
]}

Jones, Robert E. ^{[1
,3
]}

Keogh, Lauren ^{[1
,3
]}

Anguiano, Maria ^{[13
]}

Stapleton, Lance ^{[4
]}

Jia, Zhiheng ^{[4
]}

Barzily-Rokni, Michal ^{[2
]}

Canadas, Israel ^{[1
]}

Thai, Tran C. ^{[1
]}

Hammond, Marc R. ^{[2
]}

Vlahos, Raven ^{[1
,5
]}

Wang, Eric S. ^{[14
]}

Zhang, Hua ^{[1
]}

Li, Shuai ^{[1
]}

Hanna, Glenn J. ^{[1
]}

Huang, Wei ^{[1
,3
]}

Hoang, Mai P. ^{[15
]}

Piris, Adriano ^{[16
,17
]}

Eliane, Jean-Pierre ^{[15
]}

Stemmer-Rachamimov, Anat O. ^{[15
]}

Cameron, Lisa ^{[18
]}

Su, Mei-Ju ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Div Med Oncol, Boston, MA USA

[3] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA 02115 USA

[4] Gilead Sci, Foster City, CA USA

[5] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA

[6] Harvard Med Sch, Lab Syst Pharmacol, Boston, MA USA

[7] Broad Inst Harvard, Cambridge, MA USA

[8] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA

[9] Harvard Grad Program Biophys, Boston, MA USA

[10] Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA

[11] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA

[12] New Jersey Inst Technol, Dept Comp Sci, Newark, NJ 07102 USA

[13] Univ Navarra, Ctr Appl Med Res, Pamplona, Spain

[14] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA

[15] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA

[16] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA

[17] Harvard Med Sch, Boston, MA USA

[18] Dana Farber Canc Inst, Confocal & Light Microscopy Core Facil, Boston, MA 02115 USA

[19] Harvard Med Sch, Brigham & Womens Hosp, Dept Dermatol, Boston, MA USA

[20] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA USA

[21] Harvard Med Sch, Brigham & Womens Hosp, Dept Surg Oncol, Boston, MA USA

[22] MIT, Dept Mech Engn, Cambridge, MA 02139 USA

[23] Harvard Med Sch, Brigham & Womens Hosp, Div Thorac Surg, Boston, MA USA

[24] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA

来源：

CANCER DISCOVERY | 2018年 / 8卷 / 02期

关键词：

IMMUNE-CHECKPOINT BLOCKADE; REGULATORY T; KINASE TBK1; CANCER; RESISTANCE; CELLS; CTLA-4; MELANOMA; IMMUNOTHERAPY; PEMBROLIZUMAB;

D O I：

10.1158/2159-8290.CD-17-0833

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ex vivo systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination therapies. Here, we demonstrate the ability to interrogate ex vivo response to ICB using murine-and patient-derived organotypic tumor spheroids (MDOTS/PDOTS). MDOTS/PDOTS isolated from mouse and human tumors retain autologous lymphoid and myeloid cell populations and respond to ICB in short-term three-dimensional microfluidic culture. Response and resistance to ICB was recapitulated using MDOTS derived from established immunocompetent mouse tumor models. MDOTS profiling demonstrated that TBK1/IKKe inhibition enhanced response to PD-1 blockade, which effectively predicted tumor response in vivo. Systematic profiling of secreted cytokines in PDOTS captured key features associated with response and resistance to PD-1 blockade. Thus, MDOTS/PDOTS profiling represents a novel platform to evaluate ICB using established murine models as well as clinically relevant patient specimens. SIGNIFICANCE: Resistance to PD-1 blockade remains a challenge for many patients, and biomarkers to guide treatment are lacking. Here, we demonstrate feasibility of ex vivo profiling of PD-1 blockade to interrogate the tumor immune microenvironment, develop therapeutic combinations, and facilitate precision immuno-oncology efforts. (C) 2017 AACR.

引用

页码：196 / 215

页数：20

共 50 条

[1] Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids
Barbie, David A.
Jenkins, Russell
Wong, Kwok-Kin
CANCER RESEARCH, 2017, 77
[2] EX VIVO PROFILING OF PD-1 BLOCKADE USING AN ORGANOTYPIC TISSUE SLICE MODEL IN SOLID TUMORS
Ding, Lina
Sullivan, Kristin
Zhou, Chensheng
Trillo-Tinoco, Jimena
Lewin, Anne
King, Catherine
Nelson, David
Chen, Benjamin
Bowden, Michaela
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A316 - A316
[3] Ex vivo single cell RNA sequencing of tumor derived organotypic spheroids identifies a unique mesenchymal resistance program to PD-1 blockade
Portell, Andrew J.
Greene, Jonathan
Taus, Luke J.
Lizotte, Patrick
Ivanova, Elena
Menezes, Kalil O.
Aref, Amir R.
Kirschmeier, Paul
Jenkins, Russell W.
Barbie, David
Paweletz, Cloud P.
CANCER RESEARCH, 2019, 79 (13)
[4] INTERROGATION OF THE TUMOR IMMUNE MICROENVIRONMENT AND EX VIVO PROFILING OF PD-1 BLOCKADE USING THE 3D-EXPLORE EX VIVO PLATFORM OF FRESH PATIENT TUMOR TISSUE
Ruedlinger, Brittney
D'Andrea, Jasmin
Ehrhart, Jared
Altiok, Soner
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A170 - A170
[5] An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
Voabil, Paula
de Bruijn, Marjolein
Roelofsen, Lisanne M.
Hendriks, Sanne H.
Brokamp, Simone
van den Braber, Marlous
Broeks, Annegien
Sanders, Joyce
Herzig, Petra
Zippelius, Alfred
Blank, Christian U.
Hartemink, Koen J.
Monkhorst, Kim
Haanen, John B. A. G.
Schumacher, Ton N.
Thommen, Daniela S.
NATURE MEDICINE, 2021, 27 (07) : 1250 - +
[6] An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
Paula Voabil
Marjolein de Bruijn
Lisanne M. Roelofsen
Sanne H. Hendriks
Simone Brokamp
Marlous van den Braber
Annegien Broeks
Joyce Sanders
Petra Herzig
Alfred Zippelius
Christian U. Blank
Koen J. Hartemink
Kim Monkhorst
John B.A.G. Haanen
Ton N. Schumacher
Daniela S. Thommen
Nature Medicine, 2021, 27 : 1250 - 1261
[7] 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade
Aref, Amir R.
Campisi, Marco
Ivanova, Elena
Portell, Andrew
Larios, Dalia
Piel, Brandon P.
Mathur, Natasha
Zhou, Chensheng
Coakley, Raven Vlahos
Bartels, Alan
Bowden, Michaela
Herbert, Zach
Hill, Sarah
Gilhooley, Sean
Carter, Jacob
Canadas, Israel
Thai, Tran C.
Kitajima, Shunsuke
Chiono, Valeria
Paweletz, Cloud P.
Barbie, David A.
Kamm, Roger D.
Jenkins, Russell W.
LAB ON A CHIP, 2018, 18 (20) : 3129 - 3143
[8] Integrating Systems Biology and an Ex Vivo Human Tumor Model Elucidates PD-1 Blockade Response Dynamics
Smalley, Munisha
Przedborski, Michelle
Thiyagarajan, Saravanan
Pellowe, Moriah
Verma, Amit
Brijwani, Nilesh
Datta, Debika
Jain, Misti
Shanthappa, Basavaraja U.
Kapoor, Vidushi
Gopinath, Kodaganur S.
Doval, D. C.
Sabitha, K. S.
Taroncher-Oldenburg, Gaspar
Majumder, Biswanath
Majumder, Pradip
Kohandel, Mohammad
Goldman, Aaron
ISCIENCE, 2020, 23 (06)
[9] Predicting Tumor Response to PD-1 Blockade
Ding, Li
Chen, Feng
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (05): : 477 - 479
[10] PD-1 blockade does not enhance T cell reactivity to autologous tumor cells ex vivo in breast cancer.
Egelston, Colt
JOURNAL OF IMMUNOLOGY, 2015, 194

← 1 2 3 4 5 →